Among 224 patients enrolled in two multicenter clinical trials, grouped by the presence or absence of FLT3-ITD, patients with FLT3-ITD AML had significantly shorter remission durations and shorter OS than those without FLT3-ITD [30]. This evidence concerns the gene FLT3 and acute myeloid leukemia.